Mauclère P, Damond F, Apetrei C, Loussert-Ajaka I, Souquière S, Buzelay L, Dalbon P, Jolivet M, Mony Lobe M, Brun-Vézinet F, Simon F, Barin F
Laboratoire National de Santé Publique et de Référence, Centre Pasteur, Yaoundé, Cameroon.
AIDS Res Hum Retroviruses. 1997 Aug 10;13(12):987-93. doi: 10.1089/aid.1997.13.987.
We developed and evaluated two peptide-based immunoassays to confirm and discriminate between group M and group O HIV-1 infection. These assays are based on in vitro competition for antibody binding between M and O peptides. The first EIA is based on competition between group M and group O gp41 immunodominant domains and the second on competition between group O and group M V3 regions of gp120. Two panels of sera were used: the first consisted of 109 sera collected from 27 group O- and 92 group M-infected patients in whom the HIV isolates had been genotyped by sequencing or heteroduplex mobility assay. In this panel, the combination of the two assays correctly discriminated 106 samples (100% group O and 96.7% group M samples). The second panel, used for the field evaluation of the two assays, consisted of 157 samples from HIV-1-infected Cameroonian patients, 33 strains having been genotyped. The combination of the two techniques in a serogrouping algorithm discriminated 147 of these samples, 74 being HIV-1 group O and 73 group M. These results always correlated with genotyping results. The 10 sera that were not successfully classified by these assays were from early seroconverters. Altogether, the two assays clearly differentiated 263 of 276 (94.9%) samples in the two panels. On the basis of the genotyping results, the positive predictive value for group discrimination in the two panels was 100% for both GSEIA assays. Our peptide-blocking group-specific EIAs for differentiation and confirmation of HIV-1 group M and group O infection are complementary tools for epidemiological studies and surveillance of HIV-1 group O strain trafficking.
我们开发并评估了两种基于肽的免疫测定法，以确认和区分M组和O组HIV-1感染。这些测定法基于M肽和O肽之间抗体结合的体外竞争。第一种酶免疫测定法基于M组和O组gp41免疫显性结构域之间的竞争，第二种基于gp120的O组和M组V3区域之间的竞争。使用了两组血清：第一组由109份血清组成，这些血清采集自27名O组和92名M组感染患者，其中HIV分离株已通过测序或异源双链迁移率测定进行基因分型。在该组中，两种测定法的组合正确区分了106个样本（100%的O组样本和96.7%的M组样本）。用于这两种测定法现场评估的第二组由157份来自感染HIV-1的喀麦隆患者的样本组成，其中33株已进行基因分型。两种技术在血清分组算法中的组合区分了其中147个样本，74个为HIV-1 O组，73个为M组。这些结果始终与基因分型结果相关。这些测定法未成功分类的10份血清来自早期血清转化者。总之，两种测定法在两组中清晰地区分了276个样本中的263个（94.9%）。根据基因分型结果，两种gp41特异性酶免疫测定法在两组中进行组区分的阳性预测值均为100%。我们用于区分和确认HIV-1 M组和O组感染的肽阻断组特异性酶免疫测定法是流行病学研究和监测HIV-1 O组毒株传播的补充工具。
